FLT3LG (fms-associated receptor tyrosine kinase 3 ligand, FLT3L for short) is a hematopoietic cytokine encoded by the FLT3LG gene, which binds to and activates the receptor FLT3 on multipotent and common lymphoid progenitor cells to play a role. As a cytokine and growth factor, FLT3LG increases the number of immune cells (lymphocytes: B cells and T cells) by activating hematopoietic progenitor cells. FLT3LG is mainly produced by lymphocytes, especially T cells, while FLT3 is mainly expressed physiologically in DCs and pathologically expressed in malignant cells and progenitor cells. In fact, FLT3LG has been shown to bind to FLT3 on DCs, stimulating their differentiation and expansion, promoting tumor antigen cross-presentation and anticancer immune responses. However, in malignant conditions, FLT3 mutations induce receptor dimerization, leading to constitutive activation of PI3K-AKT, RAS-MEK-MAPK, and STAT-5 signaling pathways. The FLT3LG-FLT3 axis is a key pathway that promotes DC-based cross-priming of anti-leukemic T cells.
This product is designed as a tool for the delivery and expression of FLT3 Ligand mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of FLT3 Ligand mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. FLT3LG protein is about 26 kD, consisting of 235 amino acids, and the GenPept accession number is NP_001191431.